{
  "abstract": "Purpose\n\nThe effectiveness of transarterial radioembolization (TARE) depends largely on the tumor-to-non-tumor ratio (TNR): the ratio of microsphere concentration between tumor and non-tumorous liver tissue. Angiotensin II (AT-II) may improve TNR by inducing vasoconstriction primarily in arteries supplying healthy liver parenchyma. Tumor-feeding arteries, lacking neurovascular innervation, are largely unresponsive to AT-II, potentially resulting in preferential blood flow redistribution toward tumor tissue. The RADIANT study aims to evaluate whether intra-arterial AT-II infusion prior to yttrium-90 (⁹⁰Y) microsphere injection improves tumor selectivity during TARE in patients with primary or metastatic liver tumors.Materials and methods\n\nThis single-center, single-arm phase II study will include 15 patients with primary or metastatic liver tumors (any histological subtype, diameter ≥ 2 cm) referred for ⁹⁰Y glass radioembolization. Each patient serves as their own control: during work-up, technetium-99m macroaggregated albumin (99mTc-MAA) is administered without AT-II and TNR is measured on SPECT/CT. During the therapeutic procedure, AT-II is infused intra-arterially (10 µg/min over 100 s) immediately before ⁹⁰Y microsphere injection, and TNR is measured on post-treatment ⁹⁰Y PET/CT. The primary endpoint is the TNR improvement factor (TNR after ⁹⁰Y + AT-II divided by TNR after 99mTc-MAA). Secondary endpoints include toxicity and technical success of AT-II administration.Discussion\n\nThe RADIANT study will provide prospective evidence on the effect of intra-arterial AT-II infusion on tumor selectivity during ⁹⁰Y radioembolization.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands."
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 8,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Niek Wijnen"
    },
    {
      "affs": [
        0
      ],
      "name": "Marnix G E H Lam"
    },
    {
      "affs": [
        0
      ],
      "name": "Khalil Ramdhani",
      "orcid": "0000-0002-4600-4301"
    },
    {
      "affs": [
        0
      ],
      "name": "Rutger C G Bruijnen",
      "orcid": "0000-0002-5167-4027"
    },
    {
      "affs": [
        0
      ],
      "name": "Martijn M A Dietze"
    },
    {
      "affs": [
        0
      ],
      "name": "Camiel E M Kerckhaert"
    },
    {
      "affs": [
        0
      ],
      "name": "Hugo W A M de Jong"
    },
    {
      "affs": [
        0
      ],
      "name": "Maarten L J Smits",
      "orcid": "0000-0003-4735-655X"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/6gf4d06s5wed1.bib",
  "cited_by": 0,
  "doi": "10.3390/cancers18193129",
  "fulltext_url": "https://europepmc.org/articles/PMC13664447",
  "id": "6gf4d06s5wed1",
  "issns": [
    "2072-6694"
  ],
  "landing_url": "https://europepmc.org/article/MED/42882823",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2721|Hepatocellular Carcinoma Treatment and Prognosis"
    ]
  ],
  "openalex": "W7214632698",
  "pdf_url": "https://europepmc.org/articles/PMC13664447?pdf=render",
  "pmcid": "PMC13664447",
  "pmid": "42882823",
  "published": "2026-09-27",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/6gf4d06s5wed1.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:16Z",
      "native_id": "MED:42882823",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42882823"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:2072-6694",
      "subfield": "oncology"
    }
  ],
  "title": "Radioembolization with Intra-Arterial Angiotensin II to Improve Tumor-Absorbed Dose (RADIANT): A Single-Arm Phase II Study Protocol.",
  "title_text": "Radioembolization with Intra-Arterial Angiotensin II to Improve Tumor-Absorbed Dose (RADIANT): A Single-Arm Phase II Study Protocol.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:19:16Z",
  "url": "https://research.draconitic.com/paper/6gf4d06s5wed1",
  "venue": "Cancers",
  "versions": []
}